Advertisement

Potential prognostic implications of myocardial thallium-201 and iodine-123-beta-methylpentadecanoic acid dual scintigraphy in patients with Anderson–Fabry disease

  • Tomoaki Haga
  • Takahiro OkumuraEmail author
  • Satoshi Isobe
  • Fuji Somura
  • Naoaki Kano
  • Tasuku Kuwayama
  • Tsuyoshi Yokoi
  • Hiroaki Hiraiwa
  • Toru Kondo
  • Akinori Sawamura
  • Ryota Morimoto
  • Hiroshi Yamamoto
  • Kazuya Tsuboi
  • Toyoaki Murohara
Original Article
  • 4 Downloads

Abstract

Objectives

Information on the relationship between myocardial damage assessed by myocardial scintigraphy and prognosis in patients with Anderson–Fabry disease (AFD) is lacking. We therefore aimed to investigate the prognostic impacts of myocardial thallium-201 (201Tl) and iodine-123 beta-methyl 15-para-iodophenyl 3(R, S)-methylpentadecanoic acid (123I-BMIPP) dual scintigraphy in patients with AFD.

Methods

Eighteen consecutive patients with AFD underwent resting myocardial 201Tl/123I-BMIPP dual scintigraphy. Total defect scores (TDS) on both images were calculated visually according to the 17-segment model using a 5-point scoring system. The mismatch score (MS) was calculated as ‘TDS on 123I-BMIPP—TDS on 201Tl’.

Results

Six major adverse cardiac events (MACEs) were recorded during a mean follow-up of 6.7 ± 4.2 years (three heart failure requiring hospitalization and three cardiac deaths). Left ventricular mass index, left atrial diameter, brain natriuretic peptide, TDS on 123I-BMIPP, and MS were all significantly greater in patients with MACEs compared with those without. Kaplan–Meier analysis indicated that high TDS on 123I-BMIPP and high MS were associated with poor event-free survival.

Conclusion

TDS on 123I-BMIPP was a better prognostic determinant in patients with AFD than TDS on 201Tl. Myocardial 201Tl/123I-BMIPP dual scintigraphy may thus be a useful noninvasive modality for evaluating prognosis in patients with AFD.

Keywords

Anderson–Fabry disease 201Tl/123I-BMIPP dual scintigraphy Defect score Prognosis 

Notes

Funding

This research received no grant from any funding agency in the public, commercial or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest

T.O. received lecture fees from Ono Yakuhin, Medtronics, and Otsuka, and research grants from Ono Yakuhin, Bayer, Daiichi-Sankyo, and Amgen Astellas, not in connection with the submitted work. S.I. received lecture fee from FUJIFILM RI Pharma and Nihon Medi-Physics. T.M. received lecture fees and unrestricted research grants for the Department of Cardiology, Nagoya University Graduate School of Medicine, from Bayer, Daiichi-Sankyo, Dainippon Sumitomo, Kowa, MSD, Mitsubishi Tanabe, Boehringer Ingelheim, Novartis, Pfizer, Sanofi-Aventis, Takeda, Astellas, Otsuka, and Teijin.

References

  1. 1.
    Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, et al. An atypical variant of Fabry’s disease in men with left ventricular hypertrophy. N Engl J Med. 1995;333:288–93.CrossRefGoogle Scholar
  2. 2.
    MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001;38:750–60.CrossRefGoogle Scholar
  3. 3.
    Kubo T, Ochi Y, Baba Y, Hirota T, Tanioka K, Yamasaki N, et al. Prevalence and clinical features of Fabry disease in Japanese male patients with diagnosis of hypertrophic cardiomyopathy. J Cardiol. 2017;69:302–7.CrossRefGoogle Scholar
  4. 4.
    O’Mahony C, Elliot P. Anderson-Fabry disease and the heart. Prog Cardiovasc Dis. 2010;52:326–35.CrossRefGoogle Scholar
  5. 5.
    Hughes DA, Elliot PM, Shah J, Zuckerman J, Coghlan G, Brookes J, et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomized, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart. 2008;94:153–8.CrossRefGoogle Scholar
  6. 6.
    Takenaka T, Teraguchi H, Yoshida A, Taguchi S, Ninomiya K, Umekita Y, et al. Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. J Cardiol. 2008;51:50–9.CrossRefGoogle Scholar
  7. 7.
    Neely JR, Rovetto MJ, Oram JF. Myocardial utilization of carbohydrate and lipids. Prog Cardiovasc Dis. 1972;3:289–32929.CrossRefGoogle Scholar
  8. 8.
    Wakasugi S, Fischman AJ, Babich JW, Callahan RJ, Elmaleh DR, Wilkinson R, et al. Myocardial substrate utilization and left ventricular function in Adriamycin cardiomyopathy. J Nucl Med. 1993;34:1529–35.PubMedGoogle Scholar
  9. 9.
    Narus H, Arii T, Kondo T, Morita M, Ohyanagi M, Iwasaki T, et al. Fatty acid imaging of stunned myocardium: clinical usefulness of iodine 123-labeled fatty acid imaging in patients with acute myocardial infarction. J Nucl Cardiol. 1998;5:275–84.CrossRefGoogle Scholar
  10. 10.
    Shimizu M, Ino H, Okeie K, Emoto Y, Yamaguchi M, Yasuda T, et al. Cardiac dysfunction and long-term prognosis in patients with nonobstructive hypertrophic cardiomyopathy and abnormal 123I–15 (p-iodophenyl)-3 (R, S) -methylpentadecanoic acid myocardial scintigraphy. Cardiology. 2000;93:43–9.CrossRefGoogle Scholar
  11. 11.
    Zhao C, Shuke N, Okizaki A, Yamamoto W, Sato J, Ishikawa Y, et al. Comparison of myocardial fatty acid metabolism with left ventricular function and perfusion in cariomyopathies: by 123I-BMIPP SPECT and 99mTc-tetrofosmin electrocardiographically gated SPECT. Ann Nucl Med. 2003;17:541–8.CrossRefGoogle Scholar
  12. 12.
    Inoue A, Fujimoto S, Yamashina S, Yamazaki J. Prediction of cardiac events in patients with dilated cardiomyopathy using 123I-BMIPP and 201Tl myocardial scintigraphy. Ann Nucl Med. 2007;21:399–404.CrossRefGoogle Scholar
  13. 13.
    Zavadovsky KV, Gulya MO, Lishmanov YB, Levedev DI. Perfusion and metabolic scintigraphy with 123I-BMIPP in prognosis of cardiac resynchronization therapy in patients with dilated cardiomyopathy. Ann Nucl Med. 2016;30:325–33.CrossRefGoogle Scholar
  14. 14.
    Nanasato M, Hirayama H, Ando A, Isobe S, Nonokawa M, Kinoshita Y, et al. Incremental predictive value of myocardial scintigraphy with 123I-BMIPP in patients with acute myocardial infarction treated with primary percutaneous coronary intervention. Eur J Nucl Med Mol Imaging. 2016;31:1512–21.CrossRefGoogle Scholar
  15. 15.
    Tamaki N, Tadamura E, Kudoh T, Hattori N, Yonekura Y, Nohara R, et al. Prognostic value of iodine-123 labelled BMIPP fatty acid analogue imaging in patients with myocardial infarction. Eur J Nucl Med. 1996;23:272–9.CrossRefGoogle Scholar
  16. 16.
    Frustaci A, Russo MA, Francone M, Chimenti C. Microvascular angina as prehypertrophic presentation of Fabry disease cardiomyopathy. Circulation. 2014;130:1530–1.CrossRefGoogle Scholar
  17. 17.
    Zarate YA, Hopkin RJ. Lysosomal strage disease 3. Fabry’s disease. Lancet. 2008;372:1427–35.CrossRefGoogle Scholar
  18. 18.
    Berman DS, Kang X, Gransar H, Gerlach J, Friedman JD, Hayes SW, et al. Quantitative assessment of myocardial perfusion abnormality on SPECT myocardial perfusion imaging is more reproducible than expert visual analysis. J Nucl Cardiol. 2009;16(1):45–53.CrossRefGoogle Scholar
  19. 19.
    Lang RM, Luigi PB, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr. 2015;28:1–39.CrossRefGoogle Scholar
  20. 20.
    Spinelli L, Pellegrino T, Pisani A, Giudice CA, Riccio E, Imbriaco M, et al. Relationship between left ventricular diastolic function and myocardial sympathetic denervation measured by 123I-meta-iodobenzylguanidine imaging in Anderson-Fabry disease. Eur J Nucl Med Mol Imaging. 2016;43:729–39.CrossRefGoogle Scholar
  21. 21.
    Imbriaco M, Pellegrino T, Piscopo V, Petretta M, Ponsiglione A, Nappi C, et al. Cardiac sympathetic neuronal damage precedes myocardial fibrosis in patients with Anderson-Fabry disease. Eur J Nucl Med Mol Imaging. 2017;44:2266–73.CrossRefGoogle Scholar
  22. 22.
    Nishimura M, Tsukamoto K, Hasebe N, Tamaki N, Kikuchi K, Ono T. Prediction of cardiac death in hemodialysis patients by myocardial fatty acid imaging. J Am Coll Cardiol. 2008;51:139–45.CrossRefGoogle Scholar
  23. 23.
    Barenbrock M, Spieker C, Laske V, Heidenreich S, Hohage H, Bachmann J, et al. Studies of the vessel wall properties in hemodialysis patients. Kidney Int. 1994;45:1397–400.CrossRefGoogle Scholar
  24. 24.
    Amman K, Breitbach M, Ritz E, Mall G. Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol. 1998;9:1018–22.Google Scholar
  25. 25.
    Nakajima K, Shimizu K, Taki J, Uetani Y, Konishi S, Tonami N, et al. Utility of iodine-123-BMIPP in the diagnosis and follow-up of vasospastic angina. J Nucl Med. 1995;36:1934–40.PubMedGoogle Scholar
  26. 26.
    Takeishi Y, Fujiwara S, Atsumi H, Takahashi K, Sukekawa H, Tomoike H. Iodine-123-BMIPP imaging in unstable angina: a guide for interventional strategy. J Nucl Med. 1997;38:1407–11.PubMedGoogle Scholar
  27. 27.
    Kawai Y, Tsukamoto E, Nozaki T, Morita K, Sakurai M, Tamaki N. Significance of reduced uptake of iodinated fatty acid analogue for the evaluation of patients with acute chest pain. J Am Coll Cardiol. 2001;38:1888–944.CrossRefGoogle Scholar
  28. 28.
    Moon JC, Sachdev B, Elkington AG, McKenna WJ, Mehta A, Pennell DJ, et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Eur Heart J. 2003;24(23):2151–5.CrossRefGoogle Scholar
  29. 29.
    Nakajima K. Normal values for nuclear cardiology: Japanese databases for myocardial perfusion, fatty acid and sympathetic imaging and left ventricular function. Ann Nucl Med. 2010;24:125–35.CrossRefGoogle Scholar
  30. 30.
    Nakajima K, Matsumoto N, Kasai T, Matsuo S, Kiso K, Okuda K. Normal values standardization of parameters in nuclear cardiology: Japanese Society of Nuclear Medicine working group database. Ann Nucl Med. 2016;30:188–99.CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Nuclear Medicine 2019

Authors and Affiliations

  • Tomoaki Haga
    • 1
    • 2
  • Takahiro Okumura
    • 1
    Email author
  • Satoshi Isobe
    • 1
  • Fuji Somura
    • 2
  • Naoaki Kano
    • 1
  • Tasuku Kuwayama
    • 1
  • Tsuyoshi Yokoi
    • 1
  • Hiroaki Hiraiwa
    • 1
  • Toru Kondo
    • 1
  • Akinori Sawamura
    • 1
  • Ryota Morimoto
    • 1
  • Hiroshi Yamamoto
    • 3
  • Kazuya Tsuboi
    • 3
  • Toyoaki Murohara
    • 1
  1. 1.Department of CardiologyNagoya University Graduate School of MedicineNagoyaJapan
  2. 2.Department of CardiologyNagoya Central HospitalNagoyaJapan
  3. 3.LSD CenterNagoya Central HospitalNagoyaJapan

Personalised recommendations